Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Evofem Biosciences Inc (EVFM) USD0.001

Sell:$0.78 Buy:$0.80 Change: $0.0554 (6.61%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
Change: $0.0554 (6.61%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
Change: $0.0554 (6.61%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs). The Company's product, Phexxi vaginal gel, is an on-demand prescription contraceptive gel for women. Its pipeline product candidate, EVO100 vaginal gel, is evaluated for the prevention of chlamydia trachomatis infection and Neisseria gonorrhoeae in women. The Company also focuses on the development of EVO200 vaginal gel, its candidate for the reduction of recurrent bacterial vaginosis (BV).Its subsidiaries include Evofem Biosciences Operations Inc, Evofem Inc and Evofem Ltd.

Contact details

12400 High Bluff Dr Ste 600
United States
+1 (858) 5501900

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$130.02 million
Shares in issue:
155.21 million
United States
US dollar

Key personnel

  • Saundra Pelletier
    President, Chief Executive Officer, Director
  • Justin File
    Chief Financial Officer
  • Alexander Fitzpatrick
    Executive Vice President, General Counsel, Secretary
  • Russell Barrans
    Chief Commercial Officer
  • Kelly Culwell
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.